Table 2 |
|
|
Overview of recent treatment patterns of gout in the USA |
|
| Total ambulatory visits, and visits to primary care versus specialists |
|
| Total number of ambulatory care visits |
973 million |
| Number of visits for gout |
3.9 million (0.4% of total) |
| Percentage of total visits for gout to: |
|
| Primary care |
69% |
| Cardiologists |
10% |
| 'Other specialists or unknown' |
<16% |
| Rheumatologists |
<2% |
| Number of gout patient-specific anti-inflammatory prescriptions (absolute number of
prescriptions/year) |
|
| Colchicine |
~381,000 |
| NSAIDs |
~700,000 |
| Prednisone |
~341,000 |
| Number of gout patient-specific urate-lowering prescriptions (absolute number of prescriptions/year) |
|
| Allopurinol |
2.8 million |
| Probenecid |
8,000 |
| Demographics of allopurinol prescribing: percentage of gout patients that are: |
|
| Caucasian |
80% |
| African Americans |
49% |
| Asians |
19% |
|
|
|
|
Data from the 2002 calendar year extracted from the work of Krishnan et al. [4]. NSAID, nonsteroidal anti-inflammatory drug. |
|
|
Terkeltaub Arthritis Research & Therapy 2009 11:236 doi:10.1186/ar2738 |
|